mRNA 1325

Drug Profile

mRNA 1325

Alternative Names: mRNA-1325; Zika mRNA vaccine- Moderna Therapeutics

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Moderna Therapeutics
  • Class RNA; RNA vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Zika virus infection

Most Recent Events

  • 11 Jul 2018 Moderna completes enrolment in its phase I/II clinical trials in Zika virus infection (Prevention) in USA (Parenteral) (NCT03014089)
  • 01 Dec 2016 Phase-I/II clinical trials in Zika virus infection (Prevention) in USA (Parenteral) (NCT03014089)
  • 01 Sep 2016 Moderna Therapeutics receives grant from Biomedical Advanced Research and Development Authority for mRNA 1325 development in Zika virus infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top